Polynucleotides comprising a micro RNA detargeting sensor and uses thereof
Patent Information
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- STRAND THERAPEUTICS INC
- Filing Date
- 2024-07-25
- Publication Date
- 2026-06-03
AI Technical Summary
Current nucleic acid-based therapies, such as mRNA vaccines, face challenges in achieving tissue-specific and cell-specific expression of payload proteins, and existing delivery platforms are inefficient and associated with undesirable side effects.
Development of isolated polynucleotides comprising a first region encoding a payload and a second region with a sensor that specifically recognizes markers expressed by immune cells, such as microRNA miR-142, to reduce payload expression in immune cells and lymphoid tissues.
The described approach allows for selective regulation of payload expression, reducing its levels in immune cells and lymphoid tissues, thereby enhancing the therapeutic efficacy and reducing side effects of nucleic acid-based therapies.
Smart Images

Figure IMGF000070_0001 
Figure IMGF000071_0001 
Figure IMGF000072_0001